Sustained subconjunctival drug delivery systems: current trends and future perspectives

2020 ◽  
Vol 40 (9) ◽  
pp. 2385-2401 ◽  
Author(s):  
Fojan Rafiei ◽  
Hadi Tabesh ◽  
Farrokh Farzad
Author(s):  
Khatereh Khorsandi ◽  
Reza Hosseinzadeh ◽  
Homa Sadat Esfahani ◽  
Saeedeh Keyvani-Ghamsari ◽  
Saeed Ur Rahman

Author(s):  
Delly Ramadon ◽  
Maeliosa T. C. McCrudden ◽  
Aaron J. Courtenay ◽  
Ryan F. Donnelly

AbstractTransdermal drug delivery systems have become an intriguing research topic in pharmaceutical technology area and one of the most frequently developed pharmaceutical products in global market. The use of these systems can overcome associated drawbacks of other delivery routes, such as oral and parenteral. The authors will review current trends, and future applications of transdermal technologies, with specific focus on providing a comprehensive understanding of transdermal drug delivery systems and enhancement strategies. This article will initially discuss each transdermal enhancement method used in the development of first-generation transdermal products. These methods include drug/vehicle interactions, vesicles and particles, stratum corneum modification, energy-driven methods and stratum corneum bypassing techniques. Through suitable design and implementation of active stratum corneum bypassing methods, notably microneedle technology, transdermal delivery systems have been shown to deliver both low and high molecular weight drugs. Microneedle technology platforms have proven themselves to be more versatile than other transdermal systems with opportunities for intradermal delivery of drugs/biotherapeutics and therapeutic drug monitoring. These have shown that microneedles have been a prospective strategy for improving transdermal delivery systems. Graphical abstract


2019 ◽  
Vol 12 (1) ◽  
pp. 157-170 ◽  
Author(s):  
Sangeeta Mohanty ◽  
Sthitapragnya Panda ◽  
Aslesha Bhanja ◽  
Abhisek Pal ◽  
Si Sudam Chandra

Recent advances in science and technology radically changed the way we detect, treat and prevent different diseases in all aspects of human life. Rheumatoid arthritis (RA) is a chronic, systemic, progressive, autoimmune disease in which the body’s immune system whose major role is to protect the health by attacking foreign bacteria and viruses are mistakenly, attacking the joints resulting in thickened synovium, pannus formation, & destruction of bone, cartilage. Still now researchers are unable to know the exact cause of this disease. However, it is believed that genes and environmental factors play a role in development of RA. In this review, we discuss the Pathophysiology, predictors, & factors involved in pathogenesis of RA. We also discuss the Conventional therapeutic agents for Rheumatoid Arthritis. More importantly, we extensively discuss the emerging novel drug delivery systems (NDDS) like nanoparticles, dendrimers, micelles, microspheres, liposomes, and so on as these are the promising tools having successful applications in overcoming the limitations associated with conventional drug delivery systems. Although several NDDS have been used for various purposes, liposomes have been focused on due to its potential applications in RA diagnosis and therapy. In addition, we discuss the therapeutic effectiveness and challenges for RA by using these novel drug delivery systems. Finally, we conclude by discussing the future perspectives.


Sign in / Sign up

Export Citation Format

Share Document